Dr Reddy's Laboratories has acquired Haleon's global Nicotine Replacement Therapy (NRT) portfolio, excluding the US, for GBP 458 million. This includes top brands like Nicotinell, Nicabate, Thrive, and Habitrol,

Hyderabad-based pharma giant Dr Reddy’s Ltd finalizes its largest acquisition by buying British Haleon Plc’s non-US nicotine replacement therapy (NRT) business for GBP 458 million. The deal includes brands like Nicotinell,

Dr Reddy's Laboratories has completed the acquisition of Haleon plc's global Nicotine Replacement Therapy (NRT) portfolio, including brands like Nicotinell, Nicabate, Thrive and Habitrol.

DRL's Swiss subsidiary completed the acquisition through the purchase of shares of Northstar Switzerland SARL, a Haleon group company